MDMA optimizes brain chemistry for safety, openness, and compassion. AEDP uses relational interventions to enhance MDMA's effects in trauma therapy, fostering trust, intimacy, and healing attachment.
Kari Gleiser
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Aaron will discuss his work with autistic adults, emphasizing neurodiversity-affirming care and the potential of psychedelic approaches to improve mental health support for autistic individuals.
Aaron Paul Orsini, Angela Carter ND, Jeanna Eichenbaum
Stanford conducted the first trial of Magnesium-Ibogaine on Special Operations Forces Veterans with traumatic brain injury, showing significant functional improvements and high remission rates for comorbid psychiatric disorders. Further controlled
Nolan Williams
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
5-MeO-DMT, a natural tryptamine, shows psychedelic effects by acting on serotonin receptors. Clinical trials suggest its potential for rapidly reducing depression symptoms, prompting further studies for depression treatment.
Johannes Reckweg